I ka mālama ʻana i ka melanoma kiʻekiʻe, he ʻano hou o ka immunotherapy, kahi i hoʻohana ʻia ma Polani ma kahi pūʻulu o nā mea maʻi i koho ʻia, i ʻōlelo ʻia e nā poʻe loea i ka wā o ka hālāwai kūkā ma Warsaw.
ʻO ke poʻo o ke keʻena o nā maʻi maʻi palupalu, iwi a me ka melanoma ma ka Oncology Center ma Warsaw, prof. Ua ʻōlelo ʻo Piotr Rutkowski a hiki i kēia manawa, hiki i nā mea maʻi me ka melanoma holomua ke ola no ka hapalua makahiki. Mahalo i ka immunotherapy hou, e wehe ana i ka PD-1 programmed death receptor a ho'ā i ka ʻōnaehana pale e hakakā i nā maʻi maʻi maʻi, ʻo ka hapalua o nā mea maʻi e ola i 24 mau mahina. Ua lōʻihi ke ola o kekahi o lākou.
Ua hoʻopaʻa inoa ʻia nā lāʻau lapaʻau e ālai ana i ka mea hoʻokipa PD-1 i ka European Union, akā ʻaʻole i uku hou ʻia ma Polani. Eia nō naʻe, loaʻa lākou ma ka hapa nui o nā ʻāina ʻEulopa, incl. ma Slovakia, Suedena, Czech Republic, Finland, Slovenia, Bulgaria, Ireland, Spain, Denmark, Luxembourg, Austria, Greece and Great Britain. Ma waho o ka EU, ua uku hou ʻia kēia mau lāʻau lapaʻau ma United States, Canada, Israel a me Switzerland.
"Ke kali nei mākou i ka uku hou ʻana o kēia mau hoʻomākaukau, no ka mea, me ka ʻole o lākou he paʻakikī ke kamaʻilio e pili ana i ka mālama ʻana o ka metastatic melanoma kiʻekiʻe, e hāʻawi ana i kekahi mau mea maʻi i ka manaʻolana nui no ka hoʻonui ʻana i ke ola a me ka hoʻomaikaʻi ʻana i kona ʻano maikaʻi" - i ʻōlelo ʻo Prof. Rutkowski. ʻAʻole loaʻa kēia mau lāʻau i nā hopena koʻikoʻi.
I kēia manawa, ua hoʻopuka ka Agency for Health Technology Assessment and Tariffs i kahi manaʻo maikaʻi e pili ana i ka hoʻihoʻi ʻana i nā lāʻau pale PD-1 ma lalo o ka papahana lāʻau me nā lāʻau lapaʻau ʻē aʻe i ʻae ʻia no ka mālama ʻana i kēia maʻi.
ʻO ka hoʻomākaukau ʻana i ka wehe ʻana i ka PD-1 receptor, ua hoʻohana ʻia ma ko mākou ʻāina, a hiki i kēia manawa ma kahi hui o nā maʻi. Ua ʻōlelo ʻo Prof. Rutkowski i ka hihia o ka melanoma, ua hoʻohana ʻia lākou i nā maʻi ma mua o 200, 100 o lākou e ola nei. Ua mālama ʻia lākou ma ke ʻano he ʻāpana o nā hoʻokolohua lapaʻau a i ʻole i kapa ʻia ʻo Early Access Therapy Program i kālā ʻia e ka mea hana lāʻau.
"ʻO kēia papahana, i hoʻomaka ʻia ma Malaki 2015, ua hoʻopaʻa inoa i nā maʻi 61 me ka melanoma metastatic kiʻekiʻe. Mai kēia hui, 30 mau mea maʻi e mālama ʻia ”- wahi a Prof. Rutkowski.
ʻO ke kūkākūkā aupuni ma ke kahua o ka clinical oncology prof. Ua ʻōlelo ʻo Maciej Krzakowski, ke poʻo o ke keʻena maʻi kanesa o ka Oncology Center ma Warsaw, ua ʻae ʻia nā lāʻau lapaʻau e wehe i ka PD-1 receptor ma United States a me ka European Union no ka mālama ʻana i ka maʻi kanesa. Ma Polani, aia lākou i kēia manawa ma ke ʻano he ʻāpana o nā hoʻokolohua lapaʻau.
"A hiki i kēia manawa, ua hoʻohana ʻia nā lāʻau lapaʻau o kēia ʻano ma ke ʻano he lāʻau hou aʻe (pae III), i ka wā i pau ai nā koho lapaʻau ʻē aʻe. Ke noʻonoʻo ʻia nei kā lākou hoʻohana ʻana i ka lāʻau lapaʻau mua "- wahi a Prof. Krzakowski. Hoʻololi kēia i ka hoʻolālā lapaʻau no nā maʻi e like me ka melanoma kiʻekiʻe (pae IV a i ʻole hiki ke hana, pae III).
Ua wehewehe ʻo Prof. Krzakowski i ka nui o nā maʻi maʻi e pale aku i ka hoʻouka ʻia ʻana o nā cell immune o ka mea maʻi. Kāohi lākou i ka hana a ka PD-1 receptor ma ka ʻili o kēia mau cell (lymphocytes). Hoʻohana lākou i kahi hana e hoʻohana ai ke kino e pale i ka ʻōnaehana pale mai ka hana ʻino loa (e pale ana i nā maʻi autoimmune).
"ʻO nā lāʻau lapaʻau e hiki mai ana e wehe i nā mea loaʻa PD-1, e hoʻāla ana i ka ʻōnaehana pale e ʻike maikaʻi a kaua aku i nā maʻi maʻi maʻi," wahi a kahi loea aupuni.
Ua ʻae ka poʻe loea i ka wā o kahi hālāwai me nā mea nūpepa ʻaʻohe ala e hoʻoholo ai i ka mea maʻi e pōmaikaʻi mai kēia ʻano immunotherapy. I ka hihia o ka melanoma, ʻoi aku ka maikaʻi o ka pane ʻana o nā mea maʻi me ka kiʻekiʻe o ka PD-1 receptors. I Dekemaba 2015, ua ʻae ʻia kekahi o ia mau lāʻau lapaʻau no ka mālama ʻana i ka maʻi maʻi maʻi maʻi ma United States.
Ua ʻōlelo ʻo Prof. Krzakowski, ʻo ka hoʻoponopono maikaʻi ʻana i ke kālā ʻana i kēia ʻano lapaʻau e ka waihona kālā mokuʻāina ke hōʻoia ʻia ka maikaʻi i ka mea maʻi i hāʻawi ʻia. Eia kekahi, aia kekahi manawa ma hope o kekahi manawa hiki ke hoʻopau ʻia kēlā ʻano lapaʻau i ka liʻiliʻi o kekahi mau maʻi, i ka wā e hiki ai i ka ʻōnaehana pale ke hoʻomalu i ka ulu ʻana o ka maʻi neoplastic ponoʻī.
Ua ʻike ka American Society of Clinical Oncology (ASCO) i Pepeluali 2016 i ka immunotherapy (wehe i ka PD-1 receptor) ʻo ia ka mea nui loa i ka oncology ma 2015. Ua hōʻike ʻia kēia ma ka hōʻike makahiki 11th "Clinical Cancer Advances 2016". ʻO ka Immunotherapy kekahi o nā kumuhana nui o ka ʻaha kūkā makahiki a AZSCO, e hoʻomaka ana ma Chicago i ka hopena o Mei.